Pharma & Bio
Technology
Lim Jong-hoon Transfers Stake to PEF… Hanmi Group Management Control Dispute Enters a New Phase
The management control dispute at the HanmiPharm(128940) Group, which had appeared to have entered a lull for some time, has entered a new phase. This comes after Lim Jong-hoon, CEO of Hanmi Fine Chem…
Lifestyle
Dop Emerges as the Biggest Beneficiary of the Waste Management Act Amendment... Positive Signs for Reaching 50 Billion Won in Annual Revenue
DOP has emerged as the biggest beneficiary following the passage of a partial amendment to the Waste Management Act, which paves the way for the medical use of human fat. DOP, a company specializing i…
Business·Industry
AprilBio Co.,Ltd., Now Under TKG’s Wing, Launches R&D Expansion Drive with 346.8 Billion Won in Funding
AprilBio Co.,Ltd.(397030)has welcomed TKG Huchems, an affiliate of the TKG Group, as its new controlling shareholder and has entered a phase of expanding its research and development (R&D) capabilitie…
Technology
[Space Biotech, Part 1] Why Are Big Pharma Companies Heading to Space? Microgravity Is Revolutionizing New Drug Development
Global Big Pharma companies are accelerating their efforts in the space medicine market, which is expected to grow to $1.6 billion (approximately 2.46 trillion won) by 2030. Starting with Merck (MSD) …
Technology
Kim Byung-soo, CEO of TR: “From National Screening Programs to Attracting Investment... Full-Scale Push into the Digital Lung Function Tester Market”
“For chronic conditions such as asthma or chronic obstructive pulmonary disease (COPD), early treatment is crucial. Seeing patients who, had their conditions been detected and managed early on, would …
Lifestyle
[BioUSA] Jeon Young-ho, CEO of EzQuris: “Expectations for a First-in-Class Drug; Background on Joint Research with AZ”
"The idea of developing antibody drugs as small molecules caught AstraZeneca's attention. Our goal is to create treatments that more patients can use while maintaining their efficacy."Jeon Young-ho, C…
Technology
"Full-Scale Commercialization to Begin Next Year"... Space Rintec's Blueprint for Space CRO and CDMO
"Developing new drugs in space reduces costs to one-tenth of the original amount. This will create a foundation for domestic pharmaceutical companies to develop new drugs quickly and at a lower cost."…
IPO
Choi Seong-gu, CEO of FINO INC.: "Final Stages of ADC Platform Validation… Pursuing Asset Deals with Our Own Pipeline"
“I believe this will be our final attempt at an IPO. We are approaching this very cautiously, with the mindset that there will be no more chances.” (Choi Seong-gu, President of FINO INC.)PinoBio, a de…
Lifestyle
Mixed Market, Solid Footing: Psomagen and Jetema Stand Out [K-Bio Pulse]
While the domestic stock market has recently remained mixed and struggled to find a clear direction, the pharmaceutical and biotech sectors have carved out an upward trajectory. This rally is backed b…
Lifestyle
Amid a Mixed Stock Market, Psomagen, Inc. and JETEMA Co.,Ltd. Stand Out [Bio Spotlight]
While the domestic stock market has recently been showing mixed trends without a clear direction, the pharmaceutical and biotech sectors have been on an upward trend, driven by clear prospects for ear…